November 1, 1986Circulation
Amiodarone versus amiodarone and a type IA agent for treatment of patients with rapid ventricular tachycardia.
Why the study?
Does the addition of a type IA antiarrhythmic agent to amiodarone improve inducibility, cycle length, and hemodynamic tolerance in patients with rapid ventricular tachycardia?
Population
37 patients with rapid ventricular tachycardia or fibrillation induced after 14 +/- 2 days of amiodarone…
Comparison
Amiodarone plus type IA antiarrhythmic agent vs Amiodarone alone
Design
RCT, randomly assigned
Follow-up
mean 14 +/- 10 months
Authors
Discussion
Loading...
Member takes
Implication
May improve acute tolerance of induced VT on amiodarone; extends electrophysiologic data but requires clinical outcome trials.
Structured PICO
Does the addition of a type IA antiarrhythmic agent to amiodarone improve inducibility, cycle length, and hemodynamic tolerance in patients with rapid ventricular tachycardia?
P
Population
37 patients with rapid ventricular tachycardia or fibrillation (cycle length < 350 msec) induced after 14 +/- 2 days of amiodarone therapy.
I
Intervention
Amiodarone plus type IA antiarrhythmic agent (procainamide or quinidine)
C
Comparator
Amiodarone alone
O
Outcome
Inducibility of ventricular tachyarrhythmia, cycle length, and hemodynamic tolerance during repeat programmed stimulationsurrogate
The addition of a type IA agent to amiodarone increases the cycle length of induced ventricular tachycardia and improves hemodynamic tolerance, though it rarely prevents induction.
Cite This Study
Marchlinski et al. (1986) studied this question.